We would love to hear your thoughts about our site and services, please take our survey here.
CNA has mentioned splitting the SP. I hope not. does anyone knoe the ratio?
Maybe this is why the Bahamas was said that it was no good. the oil price was only $50 a barrel and to get it out it will cost $80 a barrel +, as it was non commercial type of production. maybe once the safron is sorted and commercial and coming out of the ground and the oil price is higher, then they may revert back to Bahamas and re calculate and shareholders will be rewarded by keeping the company and the fatcats a float. is this wishful thinking, CEG will probably be brought out by then or kurplunk, time will tell.
Is it true or false that Kier has a 5.5 dividend cover. this is what it says on dividend max web site?
Why do people think the students are getting ripped off!
students have choices of where to live and where they go for Uni. If the student moves into a student living property they do pay a little more then if they move into a private property, the reason being is students deface their rooms and communal areas from blocked drains to damaged walls and doors. The rent concessions for 6 weeks is kind, but I think the reason for rent increase in the summer is that the new wave of students move in.
sorry that was old news. It was when Columbus merged with BPC back in August. Just worried about the SP falling to this low.
Should of read it without being so tired.
1. KEY INFORMATION
(a) Name of exempt principal trader: Shore Capital Stockbrokers Ltd
(b) Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offeree Columbus Energy Resources Plc
(c) Name of the party to the offer with which exempt principal trader is connected: Bahamas Petroleum Company plc
(d) Date dealing undertaken: 07 August 2020
(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer? Yes
2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER
(a) Purchases and sales
Class of relevant security Purchases/ sales
Total number of securities Highest price per unit paid/received Lowest price per unit paid/received
Ordinary Sales 670,152 1.7p 1.7p
(b) Derivatives transactions (other than options)
Class of relevant security Product description
e.g. CFD Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit
(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc. Expiry date Option money paid/ received per unit
(ii) Exercising
Class of relevant security Product description
e.g. call option Number of securities Exercise price per unit
(d) Other dealings (including subscribing for new securities)
Class of relevant security Nature of dealing
e.g. subscription, conversion Details Price per unit (if applicable)
The currency of all prices and other monetary amounts should be stated.
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
3. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
If there are no such agreements, arrangements or understandings, state “none”
None
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i) the voting rights of any relevant
can someone shine some light on that Columbus energy resources have had the offer excepted from BPC of £25Million . It is on the AIM symbol CERP. and now CERP has delisted from the AIM. Should we be concerned about BPC selling out and we are not rewarded by our long invested outlook to this company?
Nurses have to be aware that this excellent wireless plaster is going to help them with their work and they will be still looking after their patients as per usual, having an instrument like this gives them more time to view each of their patients in even more detail because they already have their every 2 minute vital signs. Maybe even have more cups of coffee and less irate with patients
1 accounts ordinary To receive and adopt the financial statements together with the report of the Directors and auditors for the year ended 30 September 2012 2 remuneration ordinary To approve the Directors Remuneration Report for the year ended 30 September 2012 3 directors ordinary To re elect Mr Tim Sharpington as a Director 4 directors ordinary To re elect Mr Alistair Taylor as a Director 5 other ordinary To re appoint PricewaterhouseCooper LLP as auditors to the Company and authorise the Directors to set remuneration 6 other ordinary To authorise the Directors to allot shares pursuant to Section 551 of the Companies Act 2006 7 other special See Notice of Meeting dated 4 February 2013 8 other special THAT a general meeting other than an Annual General Meeting may be called on not less than 14 clear days notice
What made it so good back in 2011. And now the EU and PYM say the company and cogane is no good. I reckon that they are lying about how drug went and that its work was no good. The company was very positive in the past 3 months about the improvements that cogane was doing. It just doesn't make sense. The past news doesn't add up to this up to date news. * European Commission has granted Orphan Drug status to Cogane (PYM50028) for the treatment of amyotrophic lateral sclerosis (ALS) * United States Food & Drug Administration granted Orphan Drug status to Cogane for ALs in July 2011
RNS Number : 0451X Phytopharm PLC 05 February 2013 5 February 2013 Interim Management Statement Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm", the "Group" or the "Company") today issues its Interim Management Statement ("IMS") which relates to the period from 1 October 2012 to 5 February 2013 and contains information up to the date of publication of this IMS. During the period · The last patient completed participation in the CONFIDENT-PD Phase II clinical trial of Cogane™ in untreated patients with early-stage Parkinson's disease in December 2012. Results from this trial remain on track to be available in February 2013. · Further work is ongoing with a number of leading opinion leaders and charities with an interest in Cogane™ in Amyotrophic Lateral Sclerosis ("ALS") to design a clinical development plan. Provisional indications for financial and logistical support for future studies of Cogane™ as a treatment for ALS have been received. · A meeting has been held with the US Food and Drug Administration ("FDA") at which a clinical development plan for Cogane™ in ALS was agreed. Cogane™ for ALS has been granted Orphan Drug status which offers the potential for accelerated development compared with conventional drug development programs. · A Phase I study of new solid dose formulations of Cogane™ was initiated and results are expected in Q1 2013. · Our financial performance from 1 October 2012 to date continues to be in line with our expectations. Based on our current expectations Phytopharm is financed until at least the end of Q1 2014. Mr Tim Sharpington, CEO commented: "Whilst completing the CONFIDENT-PD clinical trial in Parkinson's disease the Company has been planning for the next stage of development. We have been pleased to receive the support of leading opinion leaders and charities for our development plans for Cogane™ in ALS, which we believe can add value alongside our work in Parkinson's disease. We have also had discussions with the FDA and potential pharmaceutical partners about how best to complete the development and commercialisation of Cogane™. The results from the CONFIDENT-PD clinical trial will be important in determining how our future strategy evolves and we look forward to receiving these results shortly". Cogane™ in Parkinson's disease Parkinson's disease is a movement disorder characterised by muscle rigidity, tremor and a slowing of physical movement (bradykinesia) and, in extreme cases, a loss of physical movement (akinesia). The primary symptoms are the result of altered signalling in an area of the brain, the striatum, responsible for the control of movement. This is caused by degeneration of dopaminergic neurones that project from the substantia nigra to the striatum, leading to insufficient f
xant14 I think ur best mate is on GE's i think. i havent seen or heard. apart from the day i think he found out his arse was grass, but that was only to find out about work, no answer, no help from this little black duck.it sounds to me u pushed the buttons for all that to happen, I suppose the good thing about being boss man. I have some different properties now but still the same amount, just reshuffling and building different ones like u lot do with shares.are u still havin fun with the one over there or have u got another? I think the shorters will short this until 27-29, buy afr at 110 , sxx at 22 , cey ride to 140 , fjet dont know when to buy in. say hi to the swedes and the germans as they are and where very good people and , it must be a good team now, and not listening to her winge at the farm,peace and quiet. where did they put u up in digs now?ring me when u hit the uk.
sorry for the late reply. Are u still out there fighting the -26's or are u back here? I havent scene ur best mate since he got the boot. better watch what I say ur prob best mates again. poor pantagraph,are u paying it back like what border wanted me to with van. ha ha
sorry for the late reply. Are u still out there fighting the -26's or are u back here? I havent scene ur best mate since he got the boot. better watch what I say ur prob best mates again. poor pantagraph,are u paying it back like what border wanted me to with van. ha ha
you dont need the div's your loaded must be getting cold over there now?
Phytopharm plc : Total Voting Rights 10/01/2012 | 07:41am US/Eastern 1 October 2012 In accordance with the FSA's Disclosure and Transparency Rules sourcebook transitional provision 6, Phytopharm plc ("Phytopharm") hereby notifies the market of the following: Phytopharm's issued share capital at 30 September 2012 consisted of 346,901,749 ordinary shares with voting rights. The Company did not, at that date, hold any shares in Treasury, and therefore the total number of ordinary shares in the Company with voting rights was 346,901,749. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Phytopharm plc under the FSA's Disclosure and Transparency Rules. Zoe McGowan Company Secretary This information is provided by RNS The company news service from the London Stock Exchange ENDTVRFSUFSFFESEDS distributed by
If Neuralstem can develop stem cells that can bring back from the dead literally Nerve cells In the brain. Why can't this help people with Loui Body Dementia. Why can't Neuralstem and PYM join forces and have the formula to control Parkinson's , Loui body , & Lou Gehrigs. after all re growing the nerves in the brain is a huge part of these diseases
is this movement to do with M J FOX back into acting and seeing his mental improvements from the Cogane drug working so well for him? Knowing that it is working excellent for M J FOX, that means it is working excellent for all the other people that are in the clinical stage as well
You have until 16th to by the shares not the 14th like whats getting said in previous posts
I have been following this share for quiet some time as there needs to be a new drug for P.D and A.D. as the older drugs that these patients use do not work well. Between the 13 -16th dec they have the world meeting in Miami and i think that this will give phytopharm good media and recognition for their drugs and investors will forget about these last few days with boss's leaving